Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 13Leukemia, Myeloid, Chronic-Phase 4Philadelphia Chromosome 3Leukemia 3Breast Neoplasms 3Bronchiolitis Obliterans Syndrome 2Translocation, Genetic 1Pathologic Processes 1Neoplasms by Histologic Type 1Neoplasms 1Neoplasm Metastasis 1Leukemia, Myeloid 1Hematologic Diseases 1Glioblastoma 1Bone Marrow Diseases 1Blast Crisis 1Advanced Breast Cancer (Parts 1 and 2) 1

Interventions

Imatinib Mesylate 6Cytarabine 5ponatinib 4nilotinib 4venetoclax 3fludarabine phosphate 3Mycophenolic Acid 3thymoglobulin 2fludarabine 2enasidenib 2Methotrexate 2Lenalidomide 2Cyclosporine 2Cyclophosphamide 2Azacitidine 2Antilymphocyte Serum 2quizartinib 1methanesulfonic acid 1glasdegib 1etoposide phosphate 1daratumumab 1bosutinib 1asciminib 1Whole-Body Irradiation 1Transplantation 1Temozolomide 1Tacrolimus 1Stem Cell Transplantation 1Standard of Care 1RFT5-SMPT-dgA immunotoxin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Leukemia, Myeloid × bosutinib × Clear all
NCT02130557 2021-05-18

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Pfizer

Phase 3 Completed
536 enrolled 24 charts 1 FDA
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Pathologic Processes, Philadelphia Chromosome, Translocation, Genetic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡